NCT03082300 2024-11-20
A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations
Astellas Pharma Inc
Phase 1 Terminated
Clinical Trials
3 trialsNCT02113813 2024-11-14
A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations
Astellas Pharma Inc
Phase 1 Completed
NCT02674555 2017-07-28
A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors
Astellas Pharma Inc
Phase 1 Withdrawn